Rein Therapeutics (RNTX) Other Non Operating Income (2019 - 2026)
Rein Therapeutics (RNTX) posted quarterly Other Non Operating Income of -$608000.0 for Q1 2026, down 662.96% year-over-year from $108000.0 in Q1 2025, and down 2940.0% quarter-over-quarter from -$20000.0 in Q4 2025.
Rein Therapeutics (RNTX) Other Non Operating Income (2019 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Other Non Operating Income for 8 consecutive years, with -$608000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 662.96% year-over-year to -$608000.0; the TTM figure through Mar 2026 stood at -$668000.0 (down 195.29% YoY), while the FY2025 annual figure was $48000.0, down 92.99% from the prior year.
- Other Non Operating Income eased to -$608000.0 in Q1 2026 per RNTX's latest filing, from -$20000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $336000.0 in Q4 2022 and bottomed at -$608000.0 in Q1 2026.
- Historically, Other Non Operating Income has averaged $61687.5 across 5 years, with a median of $94500.0 in 2024.
- Annual changes were most pronounced in 2023 — Other Non Operating Income soared 3800.0% — and 2026, when it sank 662.96%.
- Rein Therapeutics' Other Non Operating Income stood at $336000.0 in 2022, then plunged by 114.58% to -$49000.0 in 2023, then soared by 655.1% to $272000.0 in 2024, then plunged by 107.35% to -$20000.0 in 2025, then slumped by 2940.0% to -$608000.0 in 2026.
- Business Quant data shows RNTX's Other Non Operating Income at -$608000.0 in Q1 2026, -$20000.0 in Q4 2025, and -$89000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -299,000.00 |
| Mar 31, 2026 | -608,000.00 |
| Dec 31, 2025 | -20,000.00 |
| Sep 30, 2025 | -89,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Dec 31, 2024 | 272,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | 92,000.00 |
| Dec 31, 2023 | -49,000.00 |
| Sep 30, 2023 | 156,000.00 |
| Jun 30, 2023 | 205,000.00 |
| Mar 31, 2023 | 232,000.00 |
| Dec 31, 2022 | 336,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Mar 31, 2022 | -22,000.00 |
| Dec 31, 2021 | 71,000.00 |
| Sep 30, 2021 | 66,000.00 |
| Jun 30, 2021 | 304,000.00 |